Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in…
Elena Garralda
In her latest On target column, published by ESMO’s Daily Reporter, VHIO’s Elena Garralda reflects on the myriad research advances presented at last month’s…
The kick-off meeting of PragmaTIL, a project that will finance a pioneering academic clinical trial in advanced therapies, coordinated by…
Reported today at the ESMO Congress 2023 in Madrid, results of a VHIO prospective study point to the promise of…
Developed by VHIO investigators, VIGex is a gene expression signature that classifies solid tumors into three categories based on the…
Recently published open access in the journal Nature Communications*, an invited Comment article first authored by VHIO’s Elena Garralda, sets…
In an invited viewpoint article published in the Cancer Discovery, co-authors Elena Garralda, Executive Director of VHIO’s Research Unit for…
In her latest On target column, author Elena Garralda, Executive Director of VHIO’s Research Unit for Molecular Therapy of Cancer…
Now published by the ESMO Daily Reporter (formerly by the ESMO Perspectives online magazine), the latest edition of On Target – Gathering…
Preliminary results from a phase I clinical trial show that the first in class MYC inhibitor Omomyc (OMO-103) has few…
